Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects (Q33847642)

29 July 2017

1 reference

title

Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects (English)

1 reference

head and neck squamous cell carcinoma

29 July 2017

1 reference

I Ganly

1

1 reference

PubMed ID

10690381

29 July 2017

S B Kaye

series ordinal

2

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

11

1 reference

29 July 2017

1

1 reference

29 July 2017

11-16

1 reference

Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity

29 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

p53 serum antibodies as prognostic indicator in head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Partial vertical laryngectomy for recurrent glottic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Partial laryngectomy in the treatment of radiation-failure of early glottic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Horizontovertical laryngectomy for supraglottic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Modern brachytherapy: current state and future prospects

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Applications of brachytherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Pilot study of intraoperative high dose rate brachytherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Interstitial thermoradiotherapy for recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Gemcitabine and radiosensitization in human tumor cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Chemotherapy of squamous cell carcinoma of head and neck: the future is now.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

An electrochemotherapy model for rat tongue carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Electroporation therapy of head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Immunotherapy of malignancy by in vivo gene transfer into tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Transfer of interleukin 2 receptor genes into squamous cell carcinoma. Modification of tumor cell growth.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Evaluation of therapeutic potential of interleukin 2-expanded tumor-infiltrating lymphocytes in squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Squamous cell carcinoma with positive margins. Surgery and postoperative irradiation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008330026617

7 January 2021

Identifiers

DOI

10.1023/A:1008330026617

1 reference

release_np5lmpoolrakxbq6rca5gb3ga4

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/np5lmpoolrakxbq6rca5gb3ga4

24 November 2022

mapped directly with Wikidata item

PubMed ID

10690381

1 reference

PubMed ID

10690381